Symbols

PMVP

Pmv Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

Ample Liquidity

RSI Oversold

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PMVP

Pmv Pharmaceuticals, Inc.

A precision oncology company that develops p53-targeted small molecule drugs for the treatment of cancer

Industry

Biological Technology

Established Date

Listing Date

09/25/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pmvpharma.com

Security Type

Common stock

Office address

400 Alexander Park Drive, Suite 301, Princeton, NJ 08540

Business

Introduction

Pmv Pharmaceuticals, Inc., was incorporated in Delaware in March 2013. The company is a precision oncology company dedicated to the discovery and development of small molecule, tumor-independent therapies for p53 mutations. P53 is a well-defined tumor suppressor protein known as the "guardian of the genome," while normal or wild-type p53 has the ability to eliminate cancer cells.

Company Financials

EPS

PMVP has released its 2025 Q4 earnings. EPS was reported at -0.33, versus the expected -0.42, beating expectations. The chart below visualizes how PMVP has performed over recent quarters, highlighting trends in earnings surprises.